Phase II Study with Bevacizumab Irinotecan Association in Relapsed/Progressed Brain Tumors: A Single Institution Experience

被引：0
|
作者：
Schiavetti, A. [1 ]
Mollace, M. G. [1 ]
Fabrizio, B. [1 ]
Paiano, M. [1 ]
Dominici, C. [1 ]
Varrasso, G. [1 ]
机构：
[1] Univ Sapienza, Pediat, Rome, Italy
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-073
引用
收藏
页码：S455 / S456
页数：2
相关论文
共 50 条
  • [1] Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience
    Schiavetti, Amalia
    Varrasso, Giulia
    Mollace, Maria Giovanna
    Dominici, Carlo
    Ferrara, Eva
    Papoff, Paola
    Di Biasi, Claudio
    CHILDS NERVOUS SYSTEM, 2019, 35 (06) : 1007 - 1012
  • [2] Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience
    Amalia Schiavetti
    Giulia Varrasso
    Maria Giovanna Mollace
    Carlo Dominici
    Eva Ferrara
    Paola Papoff
    Claudio Di Biasi
    Child's Nervous System, 2019, 35 : 1007 - 1012
  • [3] Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
    Mesti, Tanja
    Moltara, Maja Ebert
    Boc, Marko
    Rebersek, Martina
    Ocvirk, Janja
    RADIOLOGY AND ONCOLOGY, 2015, 49 (01) : 80 - 85
  • [4] Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
    Modak, Shakeel
    Kushner, Brian H.
    Basu, Ellen
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (08)
  • [5] Vincristine and Irinotecan in Children with Relapsed Hepatoblastoma: A Single-Institution Experience
    Zhang, Yu-tong
    Feng, Li-hua
    Zhong, Xiao-dan
    Wang, Li-zhe
    Chang, Jian
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (01) : 18 - 25
  • [6] Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB).
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Leyco, Samantha
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience
    Kang, T.
    Jin, T.
    Peereboom, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
    Venkatramani, Rajkumar
    Malogolowkin, Marcio
    Davidson, Tom B.
    May, William
    Sposto, Richard
    Mascarenhas, Leo
    PLOS ONE, 2013, 8 (07):
  • [9] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Trafalis, Dimitrios T.
    Alifieris, Constantinos
    Stathopoulos, George P.
    Sitaras, Nikolaos
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 713 - 722
  • [10] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: PRELIMINARY RESULTS
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Basu, Ellen
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1057 - 1057
12345